Tag Archives: safety

Roche’s Itovebi Regimen Shows Significant Survival Benefits for HR-Positive Breast Cancer in Phase III Trial Results

(IN BRIEF) Roche announced the publication of pivotal phase III results for its Itovebi™ (inavolisib)-based regimen at the Clinical Trials in Alzheimer’s Disease congress, demonstrating a 57% reduction in the risk of disease progression or death in patients with HR-positive, … Read the full press release

Continental’s German Plants Achieve ISCC PLUS Certification, Advancing Sustainable Material Goals for 2050

(IN BRIEF) Continental’s ContiTech facilities in Waltershausen and Eislingen have achieved ISCC PLUS certification, marking them as the first Continental plants in Germany to reach this sustainability standard. This certification allows Continental to integrate renewable and recycled materials into its … Read the full press release

Continental’s UltraContact NXT Wins Top Innovation Award for Sustainability in Tire Design

(IN BRIEF) Continental’s UltraContact NXT tire has been awarded the Future Tire & Rubber Award 2024 by the European Rubber Journal in the “Advanced Design: Tires” category. This recognition highlights the UltraContact NXT’s use of up to 65% sustainable materials, … Read the full press release

České dráhy Secures €300 Million EIB Loan to Modernize Czech Rail Fleet for Enhanced Safety and Sustainability

(IN BRIEF) The European Investment Bank (EIB) has provided a CZK 7.61 billion (€300 million) loan to České dráhy, the Czech Republic’s national railway operator, to modernize and expand its rail fleet. The funding will enable České dráhy to purchase … Read the full press release

QIAGEN Gains FDA Approval for QIAstat-Dx Mini Panel, Enhancing Outpatient Respiratory Diagnostics with Rapid Results

(IN BRIEF) QIAGEN has announced FDA clearance for its QIAstat-Dx Respiratory Panel Mini, marking the third such approval for the QIAstat-Dx system in 2024. Tailored for outpatient settings, this panel quickly detects five common respiratory pathogens—including influenza strains and SARS-CoV-2—enabling … Read the full press release

AstraZeneca’s Fasenra Approved in EU for Treating Rare Vasculitis, Offering New Hope for EGPA Patients

(IN BRIEF) AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union as an add-on treatment for adults with eosinophilic granulomatosis with polyangiitis (EGPA), a rare and severe form of vasculitis. The approval follows positive results from the MANDARA Phase … Read the full press release

Mercedes-Benz Enhances Safety in Econic Vehicles with Pedestrian Detection and Collision Prevention Systems

(IN BRIEF) Mercedes-Benz has introduced advanced safety features in its Econic waste collection vehicles, including the fourth-generation Active Brake Assist system, which detects pedestrians and automatically initiates partial braking to avoid collisions. Additionally, Sideguard Assist helps drivers navigate urban environments … Read the full press release

EFSA Confirms Safety of Silicon Dioxide in Food, Supporting Evonik’s Silica Products for Sustainable Use

(IN BRIEF) The European Food Safety Authority (EFSA) has confirmed the safety of silicon dioxide (E 551) as a food additive, including its use in infant food, after a recent scientific review. Evonik, a major producer of silica, welcomed this … Read the full press release

Garanti BBVA and WWF Türkiye Complete Key Projects for Wildlife Protection and Forest Fire Prevention

(IN BRIEF) Garanti BBVA and WWF Türkiye have successfully completed three new projects as part of their ‘Türkiye’s Life: Fire Management Grant Program,’ launched to mitigate forest fire risks and support wildlife conservation. The projects included efforts to protect caracal … Read the full press release

Wainzua Receives EU Recommendation for Treating Hereditary Amyloidosis, Offering New Monthly Self-Administered Option

(IN BRIEF) AstraZeneca and Ionis’ drug Wainzua (eplontersen) has been recommended for approval in the European Union for treating hereditary transthyretin-mediated amyloidosis (ATTRv-PN) in adults with stage 1 or 2 polyneuropathy. Based on the positive results from the NEURO-TTRansform Phase … Read the full press release

GSK and Cambridge University Join Forces with £50 Million Investment to Tackle Kidney and Respiratory Diseases Using AI

(IN BRIEF) GSK and the University of Cambridge have announced a £50 million, five-year collaboration called the Cambridge-GSK Translational Immunology Collaboration (CG-TIC) to accelerate research and development in kidney and respiratory diseases. The initiative combines GSK’s expertise in immunology and … Read the full press release

Novo Nordisk’s Oral Semaglutide Reduces Cardiovascular Risk by 14% in Type 2 Diabetes Patients, SOUL Trial Shows

(IN BRIEF) Novo Nordisk’s SOUL trial has shown that oral semaglutide reduces the risk of major adverse cardiovascular events (MACE) by 14% in adults with type 2 diabetes and established cardiovascular disease or chronic kidney disease. The trial involved 9,650 … Read the full press release

Landis+Gyr Enhances INCH Duo Charger to Meet PAS 1899 Accessibility Standards for Inclusive EV Charging

(IN BRIEF) Landis+Gyr has upgraded its INCH Duo charging station to meet the PAS 1899 specification, aimed at improving accessibility for all users, including those with disabilities. The PAS 1899 guidelines, developed in collaboration with Motability and the Office for … Read the full press release

Novo Nordisk’s Alhemo® Recommended for European Approval as First Once-Daily Subcutaneous Treatment for Haemophilia A and B with Inhibitors

(IN BRIEF) Novo Nordisk’s Alhemo® (concizumab) has been recommended for approval by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). If approved, Alhemo® will become the first once-daily subcutaneous prophylactic treatment for people aged 12 … Read the full press release

Sanofi and Orano Med Partner to Drive Development of Advanced Radioligand Cancer Therapies

(IN BRIEF) Sanofi and Orano Med have partnered to accelerate the development of next-generation radioligand therapies (RLTs) for rare cancers. By combining their expertise, they aim to advance treatments using lead-212 (212Pb) alpha-emitting isotopes, which target and destroy cancer cells … Read the full press release

AstraZeneca Presents New Data at IDWeek 2024, Showcasing Progress in Respiratory Disease Prevention and Vaccine Innovation

(IN BRIEF) AstraZeneca presented significant advancements in the prevention of infectious diseases at IDWeek 2024, showcasing its dedication to addressing respiratory infections caused by RSV, hMPV, and COVID-19. The company revealed promising data across its portfolio, including Beyfortus, an antibody … Read the full press release

Fresenius Medical Care Unveils Xenios 2.0: Next-Generation ECLS System with Advanced Safety and Connectivity Features

(IN BRIEF) Fresenius Medical Care’s subsidiary, Xenios AG, has launched Xenios 2.0, a new system for extracorporeal life support (ECLS) that serves patients from neonates to adults. Approved under the new Medical Device Regulation (MDR), Xenios 2.0 offers advanced safety … Read the full press release

TÜV Rheinland Unveils New Certification Services at Annual Launch Event, Paving the Way for Product Advancements

(IN BRIEF) TÜV Rheinland Greater China recently held its annual new service launch event in Shenzhen, unveiling a comprehensive suite of certification services for electronic and electrical products. These services focus on diverse environments and emphasize key areas such as … Read the full press release

GSK Reports Promising Phase III Findings for Depemokimab in Treating Chronic Rhinosinusitis with Nasal Polyps

(IN BRIEF) GSK plc has announced positive results from its Phase III ANCHOR trials for depemokimab, a biologic treatment for chronic rhinosinusitis with nasal polyps (CRSwNP). The trials demonstrated a significant reduction in nasal polyp size and nasal obstruction after … Read the full press release

Roche’s Evrysdi Shows Remarkable Motor and Cognitive Outcomes in Children with SMA After Two Years of Early Treatment

(IN BRIEF) Roche has announced positive two-year data from its RAINBOWFISH study, showcasing the effectiveness of Evrysdi® (risdiplam) in treating children with spinal muscular atrophy (SMA) when administered before symptoms appear. The study revealed that most children achieved key motor … Read the full press release